Moderate

Primary myelofibrosis (PMF; myelofibrosis, idiopathic myelofibrosis, chronic idiopathic myelofibrosis; incl. post-PV/post-ET MF)

Myeloproliferative neoplasm · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Clonal MPN with marrow fibrosis, extramedullary haematopoiesis and massive splenomegaly. Leukoerythroblastic film with tear-drop cells. Presents with anaemia, constitutional symptoms, abdominal fullness, cytopenias, or thrombosis. ED role: recognise, exclude acute complications (splenic infarct, bleeding, infection, portal hypertension), refer for JAK-inhibitor/transplant assessment.

Red flags

  • Splenic infarction (acute left-upper-quadrant pain, pleuritic, rub)
  • Bleeding with thrombocytopenia
  • Febrile neutropenia / infection on cytopenia
  • Blasts on film / rapid count change (transformation to AML)
  • Portal hypertension - variceal bleed, ascites
  • Bone pain, severe constitutional symptoms (progressive disease)

Assessment

Differential diagnosis

  • Other MPN (PV, ET, CML - BCR-ABL)
  • Myelodysplastic syndrome / MDS-MPN overlap
  • Marrow infiltration (metastatic cancer, lymphoma, myeloma)
  • Secondary/reactive myelofibrosis (infection, autoimmune, vitamin deficiency)
  • Hairy cell leukaemia (also causes dry tap/splenomegaly)

Investigations

  • FBC + blood film (leukoerythroblastic: tear-drop poikilocytes, nucleated RBCs, immature myeloid cells)
  • JAK2 V617F, CALR, MPL mutation panel; BCR-ABL1 to exclude CML
  • Bone marrow aspirate (often 'dry tap') + trephine showing fibrosis (reticulin/collagen)
  • U&E, urate, LDH (raised), LFTs (portal hypertension)
  • USS abdomen - splenomegaly, portal flow
  • Risk score (DIPSS/DIPSS-plus) for prognosis

Management

  • Confirm with film + mutation + marrow; exclude CML and secondary causes
  • Treat acute presentations: splenic infarct (analgesia), bleeding, infection (cytopenic sepsis pathway), symptomatic anaemia
  • Symptomatic splenomegaly / constitutional symptoms: JAK inhibitor (ruxolitinib) - haematology-directed
  • Anaemia management: transfusion support, consider danazol/EPO/thalidomide-steroid per specialist
  • Assess transplant eligibility (only curative option) in intermediate-2/high-risk fit patients
  • Manage portal hypertension complications; VTE prophylaxis balanced against bleeding/thrombocytopenia

Drugs & doses

Ruxolitinib 15-20 mg PO twice daily (dose by platelet count), reduces spleen size and symptoms [verify local dose]
Transfuse packed red cells for symptomatic anaemia (restrictive threshold)
Hydroxycarbamide for symptomatic thrombocytosis/leucocytosis/splenomegaly [verify local dose]
Danazol / erythropoiesis-stimulating agent for anaemia per specialist [verify local dose]
Allopurinol 100-300 mg PO once daily for hyperuricaemia [verify local dose]
Allogeneic stem cell transplant - only curative therapy (eligible patients)

Disposition

Acute complication (infarct, bleed, sepsis, transformation) -> admit with haematology. Stable new diagnosis -> urgent outpatient haematology for risk scoring and treatment planning.

Complications & pitfalls

  • Leukaemic (AML) transformation
  • Progressive marrow failure (infection, bleeding, transfusion dependence)
  • Portal hypertension / extramedullary haematopoiesis
  • Splenic infarction / rupture
  • Thrombosis and cachexia

Exam pearls

  • Tear-drop cells + leukoerythroblastic film + massive splenomegaly = think myelofibrosis
  • 'Dry tap' on marrow aspirate is characteristic - trephine needed for fibrosis
  • Ruxolitinib improves symptoms/splenomegaly and survival but is not curative - only allo-transplant is
  • DIPSS/DIPSS-plus guides prognosis and transplant timing
  • Abrupt ruxolitinib withdrawal can cause a cytokine rebound ('discontinuation syndrome')

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.